Table 1. Testing results by formulation and country purchased for TLC and dissolutioni,ii .
| Ghana | Kenya | Nigeria | Rwanda | Tanzania | Uganda | Total | |
| Sulfadoxine-pyrimethamine | 50% (3/6) | 38% (6/16) | 50% (1/2) | 50% (3/6) | 27% (3/11) | 33% (3/9) | 38% (19/50) |
| Amodiaquine | 33% (2/6) | 50% (4/8) | 25% (1/4) | - | 100% (2/2) | 56% (5/9) | 48% (14/29) |
| Mefloquine | 0% (0/1) | - | 50% (1/2) | - | 0% (0/3) | 27% (3/11) | 24% (4/17) |
| Artesunate | 38% (3/8) | 0% (0/4) | 33% (2/6) | - | 31 (4/13) | 33% (6/18) | 31% (15/49) |
| Artemether | 0% (0/3) | 100% (1/1) | - | - | - | 29% (2/7) | 27% (3/11) |
| Dihydro-artemisinin | 40% (2/5) | 56% (5/9) | 100% (1/1) | - | 50% (2/4) | 67% (2/3) | 55% (12/22) |
| Artemether-lumefantrine fixed-dose combination | 38% (3/8) | 0% (0/4) | 14% (1/7) | 0% (0/3) | 0% (0/1) | 22% (2/9) | 19% (6/32) |
| Total | 35% (13/37) | 38% (16/42) | 32% (7/22) | 33% (3/9) | 32% (11/34) | 35% (23/66) | 35% (73/210) |
i.
Percentages are supported by (total that failed either dissolution or TLC/total treatments tested)
ii.
Co-packaged ACTs are listed as individual monotherapies